Local residents lay flowers at the door of the basilica in Nice a day after the knife attack
Local residents lay flowers at the door of the basilica in Nice a day after the knife attack
Three-time U.S. women's hockey Olympian Kacey Bellamy, a member of the popular 2018 gold-medal-winning team, announced her retirement on Tuesday. The 34-year-old Bellamy played 130 games over 15 years with the national team and had 11 goals and 38 assists. "Hockey has given me the most incredible memories, and as tough of a decision that this is, I know in my heart it is right," Bellamy said in her announcement.
‘The problem with #airbnb is that people are terrorists. Their homes are filthy and disgusting,’ says comedian Tim Dillon
Frightened citizens of the Israeli coastal city of Ashkelon ran for cover on Tuesday, as rockets exploded overhead... ...as the cross-border violence between Israel and Palestinian militants extended into a ninth day... with no end in sight.Just a few miles away, Natanel Sharvit, his wife, and four children have been living in an Israeli rocket shelter under the near-constant threat of attacks launched by Hamas and Islamic Jihad from the Gaza Strip, just 12 miles from their home.SHARVIT: "The kids suffer from anxieties, they're afraid to sleep in our home. As you can see we are staying in the shelter and hoping for the best, that this situation will be over and we'll be able to live better, normally."Sharvit and his family are no more in control of the air war raging above their heads than the Palestinian civilians living on the other side of the Israeli military barrier that separates north Gaza from southern Israel.Many Palestinians have fled to schools run by the U.N.'s refugee agency - like this one in Gaza City - where classrooms have become dormitories for the displaced. The U.N. Relief and Works Agency estimates that 47,000 Palestinians are now camped out in the 58 education establishments it runs in Gaza.Israeli air strikes have pounded Gaza day and night since the conflict flared on May 10, and Israel says the strikes will continue as long as necessary to destroy Hamas military sites and kill its leaders. Gaza medical officials said more than 200 Palestinians have been killed and more than 1,400 have been wounded. In Israel, authorities say 12 people have died, as of Tuesday.
The Multiple Myeloma pipeline is majorly thriving owing to the several different companies developing novel and sophisticated blockbuster drugs, increasing R&D, increasing global prevalence, better awareness and appropriate diagnosis in patients.Los Angeles, USA, May 18, 2021 (GLOBE NEWSWIRE) -- Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth with a Gamut of Pharma Companies Involved Worldwide The Multiple Myeloma pipeline is majorly thriving owing to the several different companies developing novel and sophisticated blockbuster drugs, increasing R&D, increasing global prevalence, better awareness and appropriate diagnosis in patients. DelveInsight’s ‘Multiple Myeloma Pipeline Insights’ report provides a holistic view of the pipeline therapies that are under development in preclinical as well as clinical stages of development, and growth prospects across the Multiple Myeloma domain. Some of the key takeaways from the Multiple Myeloma Pipeline report: Multiple Myeloma Pipeline report offers a comprehensive analysis of 80+ key players and 80+ key therapies.The report lays a comprehensive analysis of the Multiple Myeloma pipeline therapies and key pharmaceutical companies including Kiadis Pharma, CASI Pharmaceuticals, NOXXON Pharma, MorphoSys), Sana Biotechnology, Ayala Pharmaceuticals, Cellectar Biosciences, Bristol-Myers Squibb, Poseida Therapeutics, AbbVie/Genentech, Jansesn Research and Development, Biotest AG, Teneobio, iCell Gene Therapeutics, Juno Therapeutics, Arch Oncology, Regeneron Pharmaceuticals, Incyte Corporation, NexImmune Inc., Chongqing Precision Biotech, Novartis, CASI Pharmaceuticals, Ionis Pharmaceuticals, AgenTus Therapeutics, Biohaven Pharmaceuticals, CRISPR Therapeutics, Pfizer, GlaxoSmithKline, Seagen Inc., Heidelberg Pharma, Bluebird Bio, C4 Therapeutics, Inc., Hoffmann-La Roche, Phosplatin Therapeutics, Arcellx, Inc., HitGen Inc., Boehringer Ingelheim, I-Mab Biopharma, Celyad Oncology, Amgen and others.Out of all the emerging therapies Ciltacabtagene Autoleucel is expected to emerge as the trailblazer owing to the treatment of Multiple Myeloma. The Janssen Pharmaceutical Companies of Johnson & Johnson submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. Multiple Myeloma pipeline comprises K NK004 (Kiadis Pharma), CID 103 (CASI Pharmaceuticals), NOX-A12 (NOXXON Pharma), TJ202 (I-MAB Biopharma), SG221 (Sana Biotechnology), AL 102 (Ayala Pharmaceuticals), CLR 131 (Cellectar Biosciences), Nivolumab (Bristol-Myers Squibb), P BCMA 101 (Poseida Therapeutics), Venetoclax (AbbVie/Genentech), and several others in the different therapeutic stage of development. Some of the other novel therapies are in the Multiple Myeloma pipeline including TNB-383B, ONC201, AO-176, JCARH125, REGN5458, INCB001158, TAK-573, NEXI-002 T Cells, PHE885, CID-103, ION251, EMB-06, agenT-797, CTX120, PF-06863135, SEA-BCMA, AEVI-007, HDP-101, bb21217, CFT7455, RO7425781, PT-112, HG146, CYAD-211, AMG 701 and others. CAR-T, or chimeric antigen receptor T-cells, a new form of cancer immunotherapy is advancing rapidly in the treatment of patients with Multiple myeloma and several other advanced cancer. Currently, the B-cell maturation antigen (BCMA) is the major target for CAR T cell therapies. BCMA has several advantages as a therapeutic target in myeloma. It is expressed exclusively on plasma cells and in particularly large quantities on plasma-turned-myeloma cells.TNB-383B is a BCMA x CD3 T-cell engaging bispecific antibody being studied in relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy. TNB-383B is being developed by TeneoOne through Phase 1. AbbVie holds the exclusive right to acquire TeneoOne and lead subsequent global development and commercialization of TNB-383B. Got queries? Want to know more? Request for Sample @ Multiple Myeloma Pipeline Insights Multiple Myeloma is a malignant disorder characterized by uncontrolled proliferation of clonal plasma cells causing a wide variety of complications leading to organ dysfunction and eventually death. It is the second most prevalent hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow. Reach out @ Multiple Myeloma Pipeline: Novel therapies and emerging technologies The Multiple Myeloma pipeline report proffers a holistic view of the business opportunities, threats, prospective collaborations and agreements, strong competitors, growth strategies, failed as well as discontinued drugs. Multiple Myeloma Pipeline: Drug Portfolio DrugCompanyPhaseMoARoAK NK004Kiadis PharmaPreclinicalAntibody-dependent cell cytotoxicity; Immunologic cytotoxicity; Natural killer cell replacementsNACID 103CASI PharmaceuticalsIAntibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulantsNANOX-A12NOXXON PharmaIIChemokine CXCL12 inhibitorsNATJ202 I-MAB BiopharmaIIIAntibody-dependent cell cytotoxicity; Phagocyte stimulantsIntravenousAPG-2575Ascentage PharmaIIProto-oncogene protein c-bcl-2 inhibitorsparenteralAL 102Ayala PharmaceuticalsIAmyloid precursor protein secretase inhibitorsOralCLR 131Cellectar BiosciencesIIIonising radiation emittersIntravenousNivolumab Bristol-Myers SquibbIIIAntibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulantsIntravenousP BCMA 101Poseida TherapeuticsIIImmunologic cytotoxicity; T lymphocyte replacementsParenteralVenetoclax AbbVie/GenentechIIIApoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitorsOralRG6160GenentechIAntibody-dependent cell cytotoxicity; T lymphocyte stimulantsIntravenousHPN-217Harpoon TherapeuticsI/IIImmunologic cytotoxicity; T lymphocyte replacementsIntravenousSAR442085SanofiIAntibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulantsIntravenousPF-06863135PfizerIIAntibody-dependent cell cytotoxicity; T lymphocyte stimulantsParenteralRAPA-201 Autologous T cellsRapa TherapeuticsIIImmunologic cytotoxicity; T lymphocyte replacementsParenteral The report lays down a complete coverage of the therapeutics by development stage, product type, route of administration, molecule type, and MOA type for Multiple Myeloma across the complete product development cycle, including all clinical and non-clinical stages. Multiple Myeloma Therapeutic Assessment By Product Type MonoCombination By Stage Discovery Pre-clinicalINDPhase IPhase IIPhase IIIPre-registration By Molecule Type Small Molecule Gene TherapyStem Cell Therapy By Route of Administration IntravenousInhalationOralSubcutaneous By Mechanism of Action Antibody-dependent cell cytotoxicityProgrammed cell death-1 receptor antagonistsApoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitorsIonizing radiation emittersChemokine CXCL12 inhibitorsAmyloid precursor protein secretase inhibitorsImmunologic cytotoxicity; T lymphocyte replacementsImmunologic cytotoxicity; Natural killer cell replacements By Targets Protease Multiple Kinase By Stage and Route of AdministrationBy Stage and Product Type Scope of the Report Coverage: GlobalKey Players: Kiadis Pharma, CASI Pharmaceuticals, NOXXON Pharma, MorphoSys), Sana Biotechnology, Ayala Pharmaceuticals, Cellectar Biosciences, Bristol-Myers Squibb, Poseida Therapeutics, AbbVie/Genentech, Janssen Research and Development, Nanjing Legend Biotech, Genenta Science, Biotest AG, Teneobio, iCell Gene Therapeutics, Juno Therapeutics, Arch Oncology, Regeneron Pharmaceuticals, Incyte Corporation, NexImmune Inc., Chongqing Precision Biotech, Novartis, CASI Pharmaceuticals, Ionis Pharmaceuticals, AgenTus Therapeutics, Biohaven Pharmaceuticals, CRISPR Therapeutics, Pfizer, GlaxoSmithKline, Seagen Inc., Heidelberg Pharma, Bluebird Bio, C4 Therapeutics, Inc., Hoffmann-La Roche, Phosplatin Therapeutics, Arcellx, Inc., HitGen Inc., Boehringer Ingelheim, I-Mab Biopharma, Celyad Oncology, Amgen and othersKey Multiple Myeloma Pipeline Therapies: TNB-383B, ONC201, AO-176, JCARH125, REGN5458, INCB001158, TAK-573, NEXI-002 T Cells, PHE885, CID-103, ION251, EMB-06, agenT-797, CTX120, PF-06863135, SEA-BCMA, AEVI-007, HDP-101, bb21217, CFT7455, RO7425781, PT-112, HG146, CYAD-211, AMG 701, Nivolumab, ventoclax, RAPA-201 autologous T cells, K NK004, CID 103, NOX-A12, TJ202, APG-2575, AL 102, CLR 131 and others. Reach out @ Multiple Myeloma Pipeline: Novel therapies and emerging technologies Table of Contents 1Introduction2Executive Summary3Multiple Myeloma Overview4Multiple Myeloma Pipeline Pipeline Therapeutics5Multiple Myeloma Pipeline Therapeutic Assessment6Multiple Myeloma – DelveInsight’s Analytical Perspective7In-depth Commercial Multiple Myeloma Pipeline Assessment8Multiple Myeloma Collaboration Deals9Late Stage Multiple Myeloma Pipeline Products (Phase III and Preregistration)10Mid-Stage Multiple Myeloma Pipeline Products (Phase II)11Pre-clinical and Discovery Stage Multiple Myeloma Pipeline Products12Inactive Multiple Myeloma Pipeline Products13Multiple Myeloma Key Companies14Multiple Myeloma Key Products15Multiple Myeloma Unmet Needs16Multiple Myeloma Market Drivers and Barriers17Multiple Myeloma Future Perspectives and Conclusion18Multiple Myeloma Pipeline Analyst Views20Appendix Visit to know more of what’s covered @ Multiple Myeloma Emerging Therapies Related Reports Multiple Myeloma MarketDelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast—2030’ report. Multiple Myeloma Epidemiology ForecastDelveInsight’s ‘Multiple Myeloma (MM)- Epidemiology Forecast to 2030’ report. Car T Cell Therapy For Multiple Myeloma MarketDelveInsight’s ‘CAR T-Cell Therapy for Multiple Myeloma-Market Insights and Market Forecast-2030’ report. Refractory Multiple Myeloma MarketDelveInsight's "Refractory Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast-2030" report. Relapsed Refractory Multiple Myeloma MarketDelveInsight's "Relapsed/Refractory Multiple Myeloma (RRMM) - Market Insights, Epidemiology, and Market Forecast-2030" report. Triple Refractory Multiple Myeloma MarketDelveInsight's "Triple-refractory Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast-2030" report. Higher Risk Chronic Myelomonocytic Leukemia MarketDelveInsight's "Higher-Risk Chronic Myelomonocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2030" report. Related Posts Multiple Myeloma Market Insights Multiple Myeloma Therapies MarketRare Cancer Market Outlook About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News CONTACT: Contact Us Shruti Thakur email@example.com +1(919)321-6187 www.delveinsight.com
Washington, May 19 (PTI) An Indian national from Texas has been sentenced to 56 months in prison and three years of supervised release on the charges of kidnapping and stalking his then wife.
Pro-Palestine demonstrators marched through midtown Manhattan on May 18, stopping in front of the New York offices of the American Israel Public Affairs Committee (AIPAC).AIPAC is a lobbying group representing pro-Israel interests in the US, and is often the target of critics of the country’s policies. During Israel’s current campaign in Gaza, AIPAC has defended the military intervention, and said that Hamas uses civilians as “human shields.”On Tuesday, health officials in Gaza said that at least 213 people have been killed and more than 1,400 injured inside the Palestinian enclave since the start of Israeli strikes on May 10. At least 12 people have been reported killed inside Israel after militants in Gaza began firing thousands of rockets.On Tuesday, protesters marched through parts of midtown Manhattan, stopping in front of AIPAC’s Third Avenue offices, where this video was taken. Credit: Jason Rosenberg via Storyful
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Braxia Scientific Corp. f/k/a Champignon Brands Inc. ("Champignon") (OTC: SHRMF) between March 27, 2020 and February 17, 2021, inclusive (the "Class Period") of the important June 9, 2021 lead plaintiff deadline in the securities class action commenced by the firm.
Washington [US] May 19, (ANI): US Senate Majority Leader Charles Schumer said the Senate will vote on legislation to establish a commission to probe the January 6 attack on the Capitol, despite signs that Republicans will broadly oppose the proposal.
Washington [US], May 19 (ANI/Sputnik): United Nations Children's Emergency Fund (UNICEF) Executive Director Henrietta Fore said in a statement that the agency needs immediate access into Gaza to provide humanitarian access to children affected by the recent escalation in violence between Israel and Hamas.
The musician is pushing classical music forward with her fusion of orchestral music and trap beats.
Hundreds of corpses have been found floating in the Ganges or buried in the sand of its banks.
Markforged announced its results for the first quarter ended March 31, 2021.
‘The first thing I recall is grabbing his hair to pull him off’
Washington, May 19 (PTI) A US Congressman on Tuesday praised the efforts of Prime Minister Narendra Modi during the ongoing COVID-19 crisis and exuded confidence that Indians will overcome the challenge.
Tokyo’s restaurateurs rail against alcohol ban as Covid measures bite. Owners of izakayas in the Shimbashi district of Japan’s capital are facing an existential threat
Hi, we’re PureWow, and we love making gorgeous desserts . But we also love relaxing in the sun (aka not spending all day in the kitchen). That’s why we created...
Company will also insist that all US vendors pay employees $15 minimum wage
Tyler Myers, Brock Boeser and Travis Hamonic each collected one goal and an assist to lead the Vancouver Canucks to a 4-2 victory over the visiting Calgary Flames on Tuesday, as the clubs took one more step to finally ending their seasons. Nils Hoglander also scored for the Canucks (23-28-4, 50 points), while goaltender Thatcher Demko made 38 saves. William Lockwood, a 2016 third-round draft choice, made his NHL debut in the Vancouver win.
Google's annual conference unveils their latest tech. Here's what we found interesting.
VANCOUVER, British Columbia, May 18, 2021 (GLOBE NEWSWIRE) -- Canasil Resources Inc. (TSX-V: CLZ, DB Frankfurt: 3CC, “Canasil” or the “Company”) announces closing of a non-brokered private placement (the “Placement”) of 7,900,000 units (the Units”) at a price of $0.10 per Unit for total gross proceeds $790,000, effective May 17, 2021. The Placement was initially announced for $500,000 and subsequently increased to $750,000 through news releases on April 27 and May 11, 2021. The closing of the Placement is subject to final acceptance by the TSX Venture Exchange. The securities issuable in connection with the Placement are subject to a hold period expiring four months and one day after the date of issuance. A finder’s fee of 6% for $5,700 is payable on part of the proceeds of the Placement. The proceeds will be used to fund continued drill programs on the Company’s silver-gold exploration projects in Durango and Zacatecas States, Mexico, and for working capital. Each Unit will consist of one common share of the Company and one half of one non-transferable share purchase warrant. Each whole warrant (a “Warrant”) will be exercisable to purchase one additional common share of the Company at a price of $0.15 during the first year, increasing to $0.20 in year two following the closing of the offering. If, commencing after the fourth month after closing, the closing price of the Company’s shares exceeds $0.25 per share for a period of 20 consecutive trading days (the “Acceleration Trigger Date”), the Company will have the right to accelerate the expiry date of the Warrants to 30 days after the Acceleration Trigger Date by the issuance of a news release announcing such acceleration within three trading days of the Acceleration Trigger Date. In accordance with the Company’s Stock Option Plan, the Company has granted 1,900,000 incentive stock options to Directors, Officers, Consultants and Employees. The options are exercisable at a price of $0.15 and valid for five years from the date of grant. The options are being granted as part of the Company’s annual review of outstanding stock options under its Stock Option Plan. About Canasil: Canasil is a Canadian mineral exploration company with a strong portfolio of 100% owned silver-gold-copper-lead-zinc exploration projects in Durango and Zacatecas States, Mexico, and in British Columbia, Canada. The Company’s directors and management include industry professionals with a track record of identifying and advancing successful mineral exploration projects through to discovery and further development. The Company is actively engaged in the exploration of its mineral properties, and maintains an operating subsidiary in Durango, Mexico, with full time geological and support staff for its operations in Mexico. For further information please contact: Bahman YaminiPresident and C.E.O.Canasil Resources Inc. Tel: (604) 709-0109www.canasil.com Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.